Nuvation Bio (NUVB) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, the company generated $41.9 million in total revenue, bringing the total revenue for 2025 to $62.9 million, which includes $15.7 million in IBTROZI net U.S. product revenue for Q4 and $24.7 million for the full year [38][39] - The gross net revenue is currently around 25%, expected to slightly increase before stabilizing long term [40] - The company ended 2025 with $529.2 million in cash equivalents and marketable securities, an increase of approximately $60 million following an upfront payment from ASI [44][45] Business Line Data and Key Metrics Changes - IBTROZI has been prescribed to 432 new patients by the end of 2025, with a patient start rate approximately six times faster than the two prior ROS1 TKI launches [5][29] - The company expects that over time, the bulk of sales will come from first-line patients who stay on the drug for many years, as opposed to the current revenue driven by third-line plus patients who do not remain on therapy for long [39] Market Data and Key Metrics Changes - The company has achieved broad coverage to label for patients across the U.S., with significant growth in market share of new patients treated with a ROS1 TKI [30] - Approximately 70% of new patient starts have come from academic centers or integrated delivery networks (IDNs), with a gradual shift expected towards community centers [35] Company Strategy and Development Direction - The company is focused on increasing its prescriber base and identifying more newly diagnosed first-line patients to be treated with IBTROZI, which is expected to significantly increase the active patient population [8] - The company plans to present additional long-term IBTROZI data at multiple medical conferences in 2026 and aims to file for approval in Europe with Eisai in the first half of the year [18][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of new patient starts, particularly in the first-line setting, and believes that the patients are available for capture [48][49] - The company is optimistic about the long-term growth potential as more TKI-naive patients begin treatment with IBTROZI, which has shown a median duration of response of 50 months [39][64] Other Important Information - The company has received approval for IBTROZI in China and Japan, and has formed a strategic partnership with Eisai to develop IBTROZI in Europe and other territories [18][43] - Safusidenib, an inhibitor of mutant IDH1 for IDH1 mutant glioma, is also being developed, with a pivotal phase 3 study expected to read out in 2029 [25][26] Q&A Session Summary Question: What are the expectations for revenue guidance in 2026? - Management noted that while they are not providing specific revenue guidance, they see a robust trajectory in new patient starts and expect growth towards the first-line setting over time [48][49] Question: Can you provide an update on the current enrollment trajectory for the phase 3 study of safusidenib? - Management expressed confidence in the enrollment for the phase 3 study, indicating that patients are available and the trial will enroll on target, with results expected by 2029 [51] Question: How should we think about the seasonal bounce back in the first part of 2026? - Management acknowledged that while there was lower use in Q4, they are confident that patients are available and expect new patient diagnoses to continue [56][57] Question: What factors could drive first-line use of IBTROZI in community settings? - Management indicated that the NCCN guidelines have been beneficial in increasing TKI use and they expect continued growth in first-line use as awareness and adoption increase [68]